How to accelerate drug discovery?
Fleur joined PPSC just before the pandemic started. In this blog she shares with us how she got off to a flying start by setting up research for COVID-19 medicines.
Webinar on-demand: Hit finding for crowd-sourced disease targets
Watch this webinar to learn about Pivot Park Screening Centre (PPSC) contributions to the European Lead Factory (ELF), hit finding efforts for > 70 crowd-sourced drug targets & lessons learnt from assay development and uHTS output within ELF.
4th Annual DDS in Munich, 12 November 2020
Drug Discovery Summit (DDS) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange. More information:
Global Partnerships that drive life science dealmaking. More information:
Drug Discovery Digital, 6-16 October
Drug Discovery Summit (DDS) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange. More information:
In a paper recently published in the SLAS Discovery Journal of Biomolecular Screening, European Lead Factory (ELF) scientists from Pivot
Assay development is often based on existing protocols, but a bit of luck can do no harm!
Fleur joined PPSC just before the pandemic started. In this blog she shares with us how she got off to a flying start by setting up research for COVID-19 medicines.
The European Lead Factory selects first COVID-19 proposal
Over the last few months, as the world has grappled with the COVID-19 pandemic, the European Lead Factory has been
Knowledge for Growth 2020 – 9 & 10 September
Celebrating the 16th Knowledge for Growth event. Meet PPSC virtually at the first digital Knowledge for Growth conference.
One of the sub-projects of the MMV-PDP Consortium recently received funding from the Bill and Melinda Gates Foundation, to further develop an
ZeGlobalTox – a rapid and reliable preclinical screening tool
The zebrafish (Danio rerio) is a tropical fish with a genetic structure surprisingly similar to ours. However, they’ve become a
Novel Screening Assay for Arginase-1 Inhibitors published in SLAS Discovery
Arginase-1 is a promising new drug target for cancer immunotherapy. A novel assay technology for High-Throughput Screening (HTS) of Arginase-1
Pivot Park – Banting Building (RE2423)
Kloosterstraat 9
5349 AB Oss
The Netherlands
Pivot Park – RE2423
Industrielaan 63
5349 AE Oss
The Netherlands
